Department of Materials, Queen Mary, University of London, Mile End Road, London E1 4NS, United Kingdom.
J Biomed Mater Res A. 2010 Jul;94(1):130-6. doi: 10.1002/jbm.a.32667.
The biocompatibility of natural samarium (III) oxide, which has previously been used for treatment in bone-related diseases was determined as a first step in its evaluation as a bone implant material. Assessment for 28 days using osteoblast-like cells revealed no indications of cytotoxicity. The cells adhered and proliferated on the surface. Furthermore, the differentiation and mineralization were observed, indicating a normal biological response of the cells on the samarium (III) oxide surface. The in vitro, short term biocompatibility assessment of this oxide has indicated its biosafety with no damaging toxic effects on the cells and biofunctionality; with an appropriate cell response for a bone-contacting material. Hence, samarium (III) oxide deserves recognition in the field of biomaterials for its excellent in vitro performance and demonstrates that the class of potential bioceramics may be larger than previously thought. (c) 2010 Wiley Periodicals, Inc. J Biomed Mater Res, 2010.
将天然氧化钐（III）用于治疗与骨骼相关的疾病，此前已经确定了其生物相容性，作为评估其作为骨植入材料的第一步。使用成骨样细胞进行 28 天的评估，未显示出细胞毒性的迹象。细胞在表面黏附和增殖。此外，观察到分化和矿化，表明细胞在氧化钐（III）表面的正常生物学反应。这种氧化物的体外短期生物相容性评估表明其生物安全性，对细胞没有破坏性的毒性作用，并且具有用于与骨接触的材料的适当细胞反应。因此，氧化钐（III）因其出色的体外性能而在生物材料领域得到认可，并表明潜在的生物陶瓷的类别可能比以前认为的更大。（c）2010 年 Wiley 期刊，公司。J Biomed Mater Res，2010.
